{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:49:06Z","timestamp":1790866146889,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"16","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1016\/j.ejca.2010.06.016","type":"journal-article","created":{"date-parts":[[2010,7,17]],"date-time":"2010-07-17T08:49:16Z","timestamp":1279356556000},"page":"2973-2985","source":"Crossref","is-referenced-by-count":34,"title":["Cost-effectiveness of human papillomavirus vaccination and screening in Spain"],"prefix":"10.1016","volume":"46","author":[{"given":"Mireia","family":"Diaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"de Sanjose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Ortendahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"O\u2019Shea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue J.","family":"Goldie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Xavier","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane J.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 10","key":"10.1016\/j.ejca.2010.06.016_bib1","doi-asserted-by":"crossref","first-page":"K29","DOI":"10.1016\/j.vaccine.2008.06.019","article-title":"Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries","volume":"26","author":"Cuzick","year":"2008","journal-title":"Vaccine"},{"issue":"15","key":"10.1016\/j.ejca.2010.06.016_bib2","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1016\/j.ejca.2009.07.016","article-title":"The challenges of organising cervical screening programmes in the 15 old member states of the European Union","volume":"45","author":"Arbyn","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2010.06.016_bib3","unstructured":"Nieminen P. How to organise a successful screening programme; the examples of the Nordic countries. The international papillomavirus educational workshops. Malm\u00f6, Sweden; May 8\u201310 2009. http:\/\/webcasts.prous.com\/netadmin\/webcast_viewer\/Preview.aspx?type=0&lid=7872&pv=1&preview=False&idcl=1."},{"issue":"2","key":"10.1016\/j.ejca.2010.06.016_bib4","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/pubmed\/fdh138","article-title":"Cost-effectiveness of organized versus opportunistic cervical cytology screening in Hong Kong","volume":"26","author":"Kim","year":"2004","journal-title":"J Public Health"},{"key":"10.1016\/j.ejca.2010.06.016_bib5","unstructured":"Cervix cancer screening. IARC handbooks on cancer prevention, vol. 10. Lyon, France: IARC Press; 2005."},{"issue":"Suppl. 3","key":"10.1016\/j.ejca.2010.06.016_bib6","doi-asserted-by":"crossref","first-page":"S\/171","DOI":"10.1016\/j.vaccine.2006.05.061","article-title":"Issues in planning cervical cancer screening in the era of HPV vaccination","volume":"24","author":"Franco","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.ejca.2010.06.016_bib7","series-title":"GLOBOCAN 2002 cancer incidence, mortality and prevalence worldwide, IARC cancerbase no. 5, version 2.0","author":"Ferlay","year":"2004"},{"issue":"2","key":"10.1016\/j.ejca.2010.06.016_bib8","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ejogrb.2008.04.005","article-title":"Age at sexual initiation and number of sexual partners in the female Spanish population results from the AFRODITA survey","volume":"140","author":"de Sanjose","year":"2008","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"2","key":"10.1016\/j.ejca.2010.06.016_bib9","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/LGT.0b013e3181599c16","article-title":"Coverage and factors associated with cervical cancer screening: results from the AFRODITA study: a population-based survey in Spain","volume":"12","author":"Puig-Tintor\u00e9","year":"2008","journal-title":"J Low Genit Tract Dis"},{"issue":"15","key":"10.1016\/j.ejca.2010.06.016_bib10","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1016\/j.ejca.2009.07.017","volume":"45","author":"Anttila","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2010.06.016_bib11","unstructured":"Schick A. Budgeting for fiscal space. Organisation for economic co-operation and development, 29th annual meeting of senior budget officials, Vienna, Austria; 2008. http:\/\/www.oecd.org."},{"issue":"Suppl. 3","key":"10.1016\/j.ejca.2010.06.016_bib12","article-title":"Public health policy for cervical cancer prevention: the role of decision science, economic evaluation, and mathematical modeling","volume":"24","author":"Goldie","year":"2006","journal-title":"Vaccine"},{"issue":"33","key":"10.1016\/j.ejca.2010.06.016_bib13","doi-asserted-by":"crossref","first-page":"6257","DOI":"10.1016\/j.vaccine.2007.05.058","article-title":"Cost-effectiveness of HPV 16, 18 vaccination in Brazil","volume":"25","author":"Goldie","year":"2007","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.ejca.2010.06.016_bib14","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/aje\/kwm086","article-title":"Multiparameter calibration of a natural history model of cervical cancer","volume":"166","author":"Kim","year":"2007","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.ejca.2010.06.016_bib15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1478-7954-5-11","article-title":"Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination","volume":"5","author":"Goldhaber-Fiebert","year":"2007","journal-title":"Popul Health Metr"},{"issue":"4","key":"10.1016\/j.ejca.2010.06.016_bib16","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/ijc.24000","article-title":"HPV16\/18 vaccination to prevent cervical cancer in the Netherlands: model-based cost-effectiveness","volume":"124","author":"Coup\u00e9","year":"2009","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2010.06.016_bib17","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1017\/S0266462307080026","article-title":"Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France","volume":"24","author":"Bergeron","year":"2008","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.ejca.2010.06.016_bib18","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/hec.864","article-title":"Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis","volume":"13","author":"Devlin","year":"2004","journal-title":"Health Econ"},{"key":"10.1016\/j.ejca.2010.06.016_bib19","unstructured":"World Health Organization. Macroeconomics and health: investing in health for economic development: report of the commission on macroeconomics and health; 2001."},{"issue":"4","key":"10.1016\/j.ejca.2010.06.016_bib20","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0213-9111(02)71933-X","article-title":"What is an efficient health technology in Spain?","volume":"16","author":"Sacrist\u00e1n","year":"2002","journal-title":"Gac Sanit"},{"issue":"6","key":"10.1016\/j.ejca.2010.06.016_bib21","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa021641","article-title":"Epidemiologic classification of human papillomavirus types associated with cervical cancer","volume":"348","author":"Mu\u00f1oz","year":"2003","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ejca.2010.06.016_bib22","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1097\/01.OLQ.0000080177.82204.E0","article-title":"Cervical human papillomavirus infection in the female population in Barcelona, Spain","volume":"30","author":"de Sanjose","year":"2003","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.ejca.2010.06.016_bib23","doi-asserted-by":"crossref","first-page":"a1754","DOI":"10.1136\/bmj.a1754","article-title":"Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study","volume":"337","author":"Dillner","year":"2008","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.ejca.2010.06.016_bib24","first-page":"415","article-title":"Human papillomavirus and cervical intraepithelial neoplasia grade III\/carcinoma in situ: a case\u2013control study in Spain and Colombia","volume":"2","author":"Bosch","year":"1993","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"11","key":"10.1016\/j.ejca.2010.06.016_bib25","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1093\/jnci\/87.11.796","article-title":"Prevalence of human papillomavirus in cervical cancer: a worldwide perspective","volume":"87","author":"Bosch","year":"1995","journal-title":"JNCI"},{"key":"10.1016\/j.ejca.2010.06.016_bib26","first-page":"3","article-title":"Human papillomavirus (HPV) infection and intraepithelial neoplasia and invasive cancer of the uterine cervix: a case\u2013control study in Zaragoza, Spain","volume":"29","author":"Bernal","year":"2008","journal-title":"Infect Agent Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2010.06.016_bib27","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/00019606-199810000-00007","article-title":"Low incidence of microsatellite instability in patients with cervical carcinomas","volume":"7","author":"Rodriguez","year":"1998","journal-title":"Diagn Mol Pathol"},{"key":"10.1016\/j.ejca.2010.06.016_bib28","unstructured":"Parkin DM, Whelan SL, Ferlay J, Storm H. Cancer incidence in five continents, vol. I to VIII. Lyon: IARC CancerBase No. 7; 2005."},{"key":"10.1016\/j.ejca.2010.06.016_bib29","unstructured":"Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, et al., editors. Cancer incidence in Spain (1998\u20132002). Cancer incidence in five continents, vol. IX. IARC Scientific Publications No. 160, Lyon: IARC; 2007."},{"key":"10.1016\/j.ejca.2010.06.016_bib30","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1177\/0272989X9701700414","article-title":"Estimating CE ratios under second-order uncertainty: the mean ratio versus the ratio of the means","volume":"17","author":"Stinnett","year":"1997","journal-title":"Med Decis Making"},{"issue":"3","key":"10.1016\/j.ejca.2010.06.016_bib31","first-page":"225","article-title":"Resource use and cost analysis of managing abnormal Pap smears: a retrospective study in five countries","volume":"29","author":"Rash","year":"2008","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1016\/j.ejca.2010.06.016_bib32","unstructured":"Wright T. Cervical screening in populations vaccinated against HPV. The international papillomavirus educational workshops. Malm\u00f6, Sweden; May 8\u201310; 2009. http:\/\/webcasts.prous.com\/netadmin\/webcast_viewer\/Preview.aspx?type=0&lid=7879&pv=1&preview=False&idcl=1."},{"key":"10.1016\/j.ejca.2010.06.016_bib33","unstructured":"World Health Statistics. World health organization; 2008. http:\/\/www.who.int\/whosis\/whostat\/EN_WHS08_Full.pdf."},{"issue":"5","key":"10.1016\/j.ejca.2010.06.016_bib34","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1185\/030079908X297826","article-title":"Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland","volume":"24","author":"Szucs","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ejca.2010.06.016_bib35","doi-asserted-by":"crossref","first-page":"a769","DOI":"10.1136\/bmj.a769","article-title":"Economic evaluation of human papillomavirus vaccination in the United Kingdom","volume":"337","author":"Jit","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.ejca.2010.06.016_bib36","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1478-7547-6-4","article-title":"Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: a cost-effectiveness analysis","volume":"6","author":"Kulasingam","year":"2008","journal-title":"Cost Eff Resour Alloc"},{"key":"10.1016\/j.ejca.2010.06.016_bib37","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.1016\/j.vaccine.2009.06.039","article-title":"Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria","volume":"27","author":"Zechmeister","year":"2009","journal-title":"Vaccine"},{"issue":"15","key":"10.1016\/j.ejca.2010.06.016_bib38","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1093\/jnci\/djp183","article-title":"Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands","volume":"101","author":"De Kok","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"10.1016\/j.ejca.2010.06.016_bib39","first-page":"400","article-title":"Human papilomavirus tetravalent vaccine cost-effectiveness study","volume":"6","author":"L\u00f3pez Alemany","year":"2007","journal-title":"Rev Esp Econ Salud"},{"issue":"9","key":"10.1016\/j.ejca.2010.06.016_bib40","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S0304-5013(08)72326-4","article-title":"Impacto de la vacuna tetravalente frente al virus del papiloma humano (VPH) tipos 6, 11, 16 y 18 en las enfermedades asociadas al VPH en Espa\u00f1a","volume":"51","author":"Castellsagu\u00e9","year":"2008","journal-title":"Prog Obstet Ginecol"},{"issue":"6","key":"10.1016\/j.ejca.2010.06.016_bib41","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/eurpub\/ckn064","article-title":"Long-term clinical impact of introducing a human papillomavirus 16\/18 AS04 adjuvant cervical cancer vaccine in Spain","volume":"18","author":"Gauthier","year":"2008","journal-title":"Eur J Public Health"},{"issue":"9679","key":"10.1016\/j.ejca.2010.06.016_bib42","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(09)60691-7","article-title":"Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24\u201345years: a randomised, double-blind trial","volume":"373","author":"Mu\u00f1oz","year":"2009","journal-title":"Lancet"},{"issue":"Suppl. 10","key":"10.1016\/j.ejca.2010.06.016_bib43","doi-asserted-by":"crossref","first-page":"K53","DOI":"10.1016\/j.vaccine.2008.06.002","article-title":"An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results","volume":"26","author":"Schiller","year":"2008","journal-title":"Vaccine"},{"issue":"9686","key":"10.1016\/j.ejca.2010.06.016_bib44","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women","volume":"374","author":"Paavonen","year":"2009","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ejca.2010.06.016_bib45","doi-asserted-by":"crossref","first-page":"833","DOI":"10.2471\/BLT.06.038893","article-title":"Economic evaluation of hepatitis B vaccination in low-income countries: using cost-effectiveness affordability curves","volume":"85","author":"Kim","year":"2007","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.ejca.2010.06.016_bib46","unstructured":"United Nations (UN), Department of Economic and Social Affairs, Population Division. World population prospects: the 2004 revision. CD-ROM edition-extended dataset. United Nations publications, sales no. E.05.XIII.12. 2005."}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804910005320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804910005320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T06:00:34Z","timestamp":1559282434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804910005320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":46,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["S0959804910005320"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2010.06.016","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}